Axxam is a member of the REsolution consortium

Jun 10, 2021

Axxam announces its participation in the REsolution consortium, a public-private research partnership supported by the Innovative Medicines Initiative (IMI), to accelerate research in the field of solute carrier (SLC) class of transporters. The project, initiated on June 1, 2021 with a duration of 2 years, aims to understand how genetic variants in humans affect the function of hundreds of cellular transporters.

Dr. Lia Scarabottolo, Director of the Axxam Discovery Services Department, commented: “At Axxam we are very proud and happy to be part of the REsolution program, which represents a natural continuation of the RESOLUTE project. Together with the world-class universities, research institutes and enterprises, which form this consortium, we will contribute by interpreting the function of Solute Carrier Proteins, potentially correlated to pathologies, paving the way for the discovery of new therapies”.

For more information, please open the Press Release from the REsolution consortium

Contact us for more information






Scroll to Top